Skip to main content

Advertisement

Log in

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Further to the wellestablished association between apolipoprotein E (APOE) and Alzheimer’s disease, this gene has also been implicated in both susceptibility to, and dementia in, Parkinson’s disease (PD). However studies to date have produced contradictory findings. We conducted a case-control study in a population of 528 PD patients and 512 healthy controls and found no significant difference in allele or genotype distribution of APOE between the two groups. An updated meta-analysis showed a modest increase of APOE-ε2 carriers amongst PD patients compared to controls [P = 0.017, OR = 1.16 (95 % CI 1.03–1.31)]. 107 of our patients were incident cases participating in a populationbased epidemiological study. Longitudinal follow-up of this cohort over a mean of 5.0 ± 0.7 years from diagnosis revealed no significant impact of APOE-ε4 carrier status on risk of dementia or rate of cognitive decline. An updated meta-analysis indicated an over-representation of APOE-ε4 carriers amongst PD dementia compared to non dementia cases [OR 1.74 (1.36–2.23), P = 1 × 10–4], although small sample sizes, heterogeneity of odds ratios and publication bias may have confounded this finding. In conclusion, our study does not support previously reported associations between APOE genotype and susceptibility to, or cognitive decline in, PD. An updated meta-analysis indicates any association with PD susceptibility is at most modest, an observation with important implications for further study of this issue. Large scale longitudinal studies would be best placed to further evaluate any impact of APOE genotype on cognitive decline in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blazquez L, Otaegui D, Saenz A, Paisan-Ruiz C, Emparanza JI, Ruiz- Martinez J, Moreno F, Marti-Masso JF, Lopez de Munain A (2006) Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson’s disease. Neurosci Lett 406:235–239

    Article  PubMed  CAS  Google Scholar 

  2. Bon MA, Jansen Steur EN, de Vos RA, Vermes I (1999) Neurogenetic correlates of Parkinson’s disease: apolipoprotein- E and cytochrome P450 2D6 genetic polymorphism. Neurosci Lett 266:149–151

    Article  PubMed  CAS  Google Scholar 

  3. Buchanan DD, Silburn PA, Prince JA, Mellick GD (2007) Association of APOE with Parkinson disease age-atonset in women. Neurosci Lett 411:185–188

    Article  PubMed  CAS  Google Scholar 

  4. Camicioli R, Rajput A, Rajput M, Reece C, Payami H, Hao C (2005) Apolipoprotein E epsilon4 and catechol-Omethyltransferase alleles in autopsyproven Parkinson’s disease: relationship to dementia and hallucinations. Mov Disord 20:989–994

    Article  PubMed  Google Scholar 

  5. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak- Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261:921–923

    Article  PubMed  CAS  Google Scholar 

  6. Dudbridge F (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25:115–121

    Article  PubMed  Google Scholar 

  7. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278:1349–1356

    Article  PubMed  CAS  Google Scholar 

  8. Feldman B, Chapman J, Korczyn AD (2006) Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol Scand 113:14–17

    Article  PubMed  CAS  Google Scholar 

  9. Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 127:550–560

    Article  PubMed  Google Scholar 

  10. Foltynie T, Sawcer S, Brayne C, Barker RA (2002) The genetic basis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:363–370

    Article  PubMed  CAS  Google Scholar 

  11. Fung HC, Scholz S, Matarin M, Simon- Sanchez J, Hernandez D, Britton A, Gibbs JR, Langefeld C, Stiegert ML, Schymick J, Okun MS, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Peckham E, De Vrieze FW, Gwinn- Hardy K, Hardy JA, Singleton A (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5:911–916

    Article  PubMed  CAS  Google Scholar 

  12. Gallardo G, Schluter OM, Sudhof TC (2008) A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 11:301–308

    Article  PubMed  CAS  Google Scholar 

  13. Ghebremedhin E, Del Tredici K, Vuksic M, Rub U, Thal DR, Burbach GJ, Rosenberger A, Bickeboller H, Deller T, de Vos RA, Jansen Steur EN, Braak H (2006) Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J Neuropathol Exp Neurol 65:116–123

    PubMed  CAS  Google Scholar 

  14. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ (2007) Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 62:145–153

    Article  PubMed  CAS  Google Scholar 

  15. Higuchi S, Matsushita S, Nakane J, Arai H, Matsui T, Urakami K, Yuzuriha T, Takeda A (2000) Alpha2-macroglobulin gene polymorphisms show racial diversity and are not associated with Alzheimer’s disease. Neuroreport 11:1167–1171

    Article  PubMed  CAS  Google Scholar 

  16. Huang X, Chen P, Kaufer DI, Troster AI, Poole C (2006) Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 63:189–193

    Article  PubMed  Google Scholar 

  17. Huang X, Chen PC, Poole C (2004) APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62:2198–2202

    PubMed  CAS  Google Scholar 

  18. Jasinska-Myga B, Opala G, Goetz CG, Tustanowski J, Ochudlo S, Gorzkowska A, Tyrpa J (2007) Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol 64:261–265

    Article  PubMed  Google Scholar 

  19. Klein C, Lohmann-Hedrich K (2007) Impact of recent genetic findings in Parkinson’s disease. Curr Opin Neurol 20:453–464

    Article  PubMed  CAS  Google Scholar 

  20. Lopez M, Guerrero J, Yescas P, Boll MC, Familiar I, Ochoa A, Rasmussen A, Alonso ME (2007) Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord 22:417–420

    Article  PubMed  Google Scholar 

  21. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pant PV, Frazer KA, Cox DR, Ballinger DG (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77:685–693

    Article  PubMed  CAS  Google Scholar 

  22. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA (2000) Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson’s disease. Mov Disord 15:714–719

    Article  PubMed  CAS  Google Scholar 

  23. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC (2006) Presence of an APOE4 allele results in significantly earlier onset of Parkinson’s disease and a higher risk with dementia. Mov Disord 21:45–49

    Article  PubMed  Google Scholar 

  24. Papapetropoulos S, Farrer MJ, Stone JT, Milkovic NM, Ross OA, Calvo L, McQuorquodale D, Mash DC (2007) Phenotypic associations of tau and ApoE in Parkinson’s disease. Neurosci Lett 414:141–144

    Article  PubMed  CAS  Google Scholar 

  25. Porter B, Macfarlane R, Unwin N, Walker R (2006) The prevalence of Parkinson’s disease in an area of North Tyneside in the North-East of England. Neuroepidemiology 26:156–161

    Article  PubMed  Google Scholar 

  26. Troster AI, Fields JA, Paolo AM, Koller WC (2006) Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson’s disease. J Neurol Sci 248:62–67

    Article  PubMed  Google Scholar 

  27. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798

    Article  PubMed  CAS  Google Scholar 

  28. Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA (2006) Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson’s disease cohort. J Neurol Neurosurg Psychiatry 77:665–667

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. H. Williams-Gray.

Additional information

These authors contributed equally to this work and should be regarded as joint first authors.

These authors contributed equally to this work and should be regarded as joint senior authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams-Gray, C.H., Goris, A., Saiki, M. et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease. J Neurol 256, 493–498 (2009). https://doi.org/10.1007/s00415-009-0119-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-0119-8

Key words

Navigation